Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

Olliaro, P. ; Sundar, S. (2009) Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India Tropical Medicine & International Health, 14 (1). pp. 88-92. ISSN 1360-2276

Full text not available from this repository.

Official URL: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-...

Related URL: http://dx.doi.org/10.1111/j.1365-3156.2008.02195.x

Abstract

Objective and method  To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India. Results  Paromomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119 250 at the current private market price or $64 383–$75 129 at preferential public sector price depending on the size of the order. With AmBisome® it would be $163 600 or $229 500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3 weeks for paromomycin; intravenous devices and hospitalization for AmBisome®; directly observed treatment if applied for miltefosine) and indirect costs. Conclusion  These calculations provide useful basic information for projections.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons.
Keywords:Visceral Leishmaniasis; Treatment Cost; Antimony Resistance; Paromomycin; Miltefosine; Liposomal Amphotericin B
ID Code:94529
Deposited On:17 Sep 2012 11:12
Last Modified:17 Sep 2012 11:12

Repository Staff Only: item control page